In vivo evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor.
Nanomedicine (Lond)
; 10(4): 589-601, 2015 Mar.
Article
in En
| MEDLINE
| ID: mdl-25723092
ABSTRACT
AIM & METHODS:
The aim of the present work was to encapsulate paclitaxel (Ptx) in various lipid nanocapsules (LNCs) formulations and then to compare their pharmacokinetics and efficacy on a subcutaneous isograft model in rats.RESULTS:
Three different Ptx formulations were obtained. Drug payloads ranged from 1.32 to 3.62 mg Ptx/g of formulation. After oral administration the area under concentration-time curve was higher (p < 0.05) if Ptx was encapsulated, (1,2 Distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(PEG)] (DSPE-PEG-NH2)) LNCs displaying the highest area under concentration-time curve (p < 0.05). Efficacy was better than control for standard LNCs after oral administration (p < 0.05) and for (DSPE-PEG-NH2) LNCs after intravenous administration. Despite good absorption, (DSPE-PEG-NH2) LNCs failed to remain efficient after oral route.CONCLUSION:
This study highlights the importance of efficacy studies paired to pharmacokinetic studies for nanomedicines.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Phosphatidylethanolamines
/
Polyethylene Glycols
/
Paclitaxel
/
Nanocapsules
/
Glioma
/
Antineoplastic Agents, Phytogenic
Limits:
Animals
/
Female
/
Humans
Language:
En
Journal:
Nanomedicine (Lond)
Year:
2015
Document type:
Article
Affiliation country:
France